Voters face Proposition 38 on the November 3, 2026 ballot, an $8.4 billion general obligation bond initiative to fund immunology and immunotherapy research at California public and nonprofit institutions, with at least half directed to cancer, heart disease, and Alzheimer’s. Trader consensus favoring rejection centers on the projected $500–600 million annual General Fund repayment cost over roughly 20–25 years, alongside concerns that eligibility criteria effectively channel about half the proceeds to a single UCLA-affiliated institute. A competing broader science bond measure failed to qualify, leaving this narrowly focused proposal as the sole research bond on the ballot amid ongoing state fiscal pressures and federal research funding uncertainty. No major campaign developments have shifted positioning since the measure qualified in June 2026.